StockData
Perspective Therapeutics, Inc. logo

Perspective Therapeutics, Inc. (CATX) stock

CATXNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 4/30
$0.75−0.03 (-3.85%)

Close on Nov 20, 2026Market cap $86.05MP/E –Yield –

Perspective Therapeutics enterprise value

Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.

Perspective Therapeutics's enterprise value was -$141.22M on Nov 11, 2026, against $2.18M a year earlier. Over the last 5 years it ranged from -$141.22M to $774.07M, with a median of $19.39M.

Enterprise Value at the end of each year

PeriodPeriod endValueChange
2026Nov 11, 2026-$141.22M-542.5%
2025Dec 31, 2025$31.91M–
2024Dec 31, 2024-$50.64M-4284.2%
2023Dec 29, 2023$1.21M–
2022Dec 30, 2022-$20.38M–
2021Dec 31, 2021-$6.66M-122.9%
2020Dec 31, 2020$29.06M-22.5%
2019Dec 31, 2019$37.50M+240.7%
2018Dec 31, 2018$11.01M-25.2%
2017Dec 29, 2017$14.71M-19.2%
2016Dec 30, 2016$18.20M-52.4%
2015Dec 31, 2015$38.23M-43.8%
2014Dec 31, 2014$68.03M+388.5%
2013Dec 31, 2013$13.93M-36.6%
2012Dec 31, 2012$21.96M+38.2%
2011Dec 30, 2011$15.89M–

More Perspective Therapeutics figures

See a number that looks wrong?